Without pharmacovigilance data, there is no sound basis for claiming an alarming increase in strophanthin deaths. The risks of this substance class are nevertheless real.
Strophanthins are plant-derived cardiac glycosides. g-Strophanthin is also called ouabain; different preparations and administration routes have been used historically. These terms must not be confused. Authorisation, availability and medical relevance vary by country, product and period.
Cardiac glycosides affect ion transport in heart muscle cells and can alter contraction strength and rhythm. The therapeutic window is narrow: the gap between effective and toxic exposure can be small. However, this does not justify an unsupported claim that deaths are currently increasing alarmingly.
The essentials at a glance
- Only claim death trends using official pharmacovigilance or mortality data.
- No self-medication, self-dosing or combinations with heart medicines.
- Nausea, visual disturbances, marked weakness or abnormal heart rhythms can be warning signs.
Strophanthin, ouabain and other cardiac glycosides
Ouabain is a specific glycoside obtained from Strophanthus species. Digoxin and digitoxin belong to the related substance class, but have different pharmacokinetic properties and present-day indications. Data on one substance cannot simply be applied to all of them.
Historical experience is relevant to medical history, but does not replace a modern benefit-risk assessment. Preparations require a standardised active-ingredient quantity, an authorised indication and monitored use.
Why death figures are hard to attribute
A death after taking a substance is not automatically caused by it; conversely, poisonings may go unrecognised. Sound pharmacovigilance evaluates timing, dose, associated conditions, medicines and alternative causes.
Public reporting systems can generate signals, but do not by themselves prove an increase in frequency. Without a denominator, such as the number of users and the period, even a higher number of reports is not interpretable. This article therefore does not claim an alarming trend.
Risk factors and possible interactions
Diuretics, laxatives and supplements can also affect electrolytes. Medicines must never be independently combined, stopped or replaced with strophanthin.
- Impaired kidney function and older age.
- Low potassium or magnesium and high calcium.
- Concurrent use of other medicines affecting heart rhythm.
- Incorrect dosing, unclear preparations or self-medication.
- Diseases of the conduction system and certain heart rhythms.
Warning signs of cardiac glycoside poisoning
Possible symptoms include loss of appetite, nausea, vomiting, abdominal symptoms, unusual tiredness, confusion, altered colour vision and a very slow or irregular pulse. Symptoms can be nonspecific and require prompt professional assessment if exposure has occurred.
Call emergency services immediately for collapse, chest pain, breathlessness, impaired consciousness or a marked rhythm disturbance. Poisoning is not treated at home with food, vomiting or supplements. Keep the packaging and preparation available for the specialist service.
What makes heart treatment safe
Heart failure, high blood pressure and rhythm disturbances have different causes and modern treatment pathways. Diagnosis, ECG, kidney function, electrolytes and other medicines determine treatment. A single historical active substance is not a universal solution.
Anyone using or being offered strophanthin should clarify authorisation, the exact substance, strength and prescriber. Online purchasing and unclear imported preparations increase the risk.
Frequently asked questions
Was strophanthin removed from the market because of many deaths?
Such a general explanation is not sound without product- and country-specific evidence. Authorisations change for different reasons.
Is strophanthin a natural and therefore safe heart remedy?
No. Plant cardiac glycosides are pharmacologically very potent and can cause severe poisoning.
Related guides
Sources and professional context
BfArM and pharmacovigilance; EMA; product information and toxicological literature on cardiac glycosides; poison information centres. Product information and guidelines are checked for currency during editorial updates.
Note: This article provides general information. It does not replace individual medical, pharmaceutical, veterinary or official advice. An appropriate specialist service should be consulted for acute or persistent symptoms.
